Intravenous Skyrizi (risankizumab-rzaa) Coverage for Crohn's Disease and Ulcerative Colitis
Customize your policy alerts
Sign up for Colorado Rocky Mountain Health Plans Policy CS2026D00116K alerts
Get alerted when Policy CS2026D00116K changes without checking for updates manually.
Monitor payer policy activity
This medical benefit drug policy governs prior authorization and medical necessity for intravenous Skyrizi used for moderately to severely active Crohn's disease or ulcerative colitis. Self-administered subcutaneous Skyrizi is obtained under the pharmacy benefit.
The policy added language stating that this Medical Benefit Drug Policy does not apply to Florida and directing readers to the state's Medicaid clinical policy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.